Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).
| Autor: | Niazi, Tamim, Nguyen, Paul L., Williams, Scott, Stockler, Martin R., Martin, Andrew James, Horvath, Lisa, Thomas, Hayley, Zebic, Danka Sinikovic, Roncolato, Felicia, Lim, Tee, Jose, Chakiath, Martin, Jarad, Chung, Hans T., Ebacher, Annie, Morgan, Scott C., Hughes, Simon, McBride, Sean Matthew, Kelly, Paul J., Davis, Ian D., Sweeney, Christopher |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p328-328, 97p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|